1. Nvidia
Nvidia, one of the most recognizable AI stocks on the market today, is an obvious choice for investors seeking an alternative to Figure. Since Nvidia participated in Figure's Series B funding round, providing a $50 million investment, investors can gain indirect exposure to Figure by buying Nvidia stock.
Nvidia is also exploring its own solutions for facilitating the development of humanoid robots. In March 2024, Nvidia announced Groot, which it characterizes as a "general-purpose foundation model that promises to transform humanoid robot learning in simulation and the real world."
Broadly speaking, Nvidia announced several solutions -- an upgraded platform, for example -- that are helping leading companies, like Boston Dynamics, Agility Robotics, and Figure, advance humanoid robotics through model training.
2. Symbotic
The company may not make robots in human form, but Symbotic (SYM -7.34%) is a leader in manufacturing AI-enabled robots that provide an autonomous solution to keep the supply chain moving. The value the company offers customers is hardly trivial.
According to Symbotic, its platform fulfills orders with 99.9999% accuracy, helping customers reduce operating costs. In addition to Walmart (NYSE:WMT), Symbotic's customers include retail leaders like Target (TGT -0.50%) and Albertsons (ACI -0.99%).
In January 2025, Symbotic announced its plan to acquire Walmart's Advanced Systems and Robotics business. With the acquisition, Symbotic estimates that it will add more than $5 billion to its backlog.
Investors interested in the growth opportunity Figure represents may find Symbotic especially appealing. Over the next 15 years, Symbotic predicts a market opportunity of $144 billion.
3. Intuitive Surgical
Intuitive Surgical (ISRG -0.76%) manufactures robotic systems, such as its da Vinci surgical system, which assists surgeons in performing minimally invasive procedures in the operating room.
Since doctors first began using the da Vinci system, it has been used in more than 20.4 million urology, gynecology, and general surgery procedures conducted in more than 12,000 hospitals worldwide.
In March 2024, Intuitive announced that the Food and Drug Administration (FDA) granted clearance to its fifth-generation surgical system platform, da Vinci 5. This platform has 150 improvements over previous models, including greater computing power and force-sense technology. In early 2026, Intuitive announced that the FDA granted clearance of the da Vinci 5 system for certain cardiac procedures, including mitral valve repair and internal mammary artery mobilization for cardiac revascularization.
Management expects continued adoption of its systems, with da Vinci procedures expected to increase by approximately 13.5% to 15.5% in 2026 compared to 2025.